CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Nebivololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01665508
NCT01665508Phase 4Completed
CompareCT.gov

Nebivolol for the Relief of Microvascular Angina in Women

Massachusetts General Hospital·interventional·Posted Aug 15, 2012·Updated Apr 20, 2017

In Brief

A Phase 4 clinical trial evaluating Nebivolol for Microvascular Angina. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Women have less significant blockages of coronary arteries, however have greater symptoms and worse outcomes compared to their age-matched male counterparts. This paradox has led to the recognition and importance of the microvasculature ( small vessels) as a contributor to symptoms and outcomes. Nebivolol has unique antioxidant properties and dilates blood vessels and it is therefore proposed that treatment with nebivolol will reduce angina (chest symptoms) in women with microvascular disease as well as improve exercise capacity, reduce resource utilization and improve other measures of artery function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrovascular Angina
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 15, 2012
Enrollment StartApr 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.9 years ago

Interventions

Nebivololdrug

Patient to start nebivolol and have repeat testing in 3 months